The Gabelli Healthcare & Wellness Trust (GRX) Key Metrics
GRX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $146.8M
- Enterprise value
- $0
- P/E (TTM)
- 17.7 10-yr median 7.2
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 17.1 10-yr median 8.4
- Price / book
- 0.9 10-yr median 0.9
- EV / EBITDA
- — 10-yr median 10.3
- Dividend yield
- 6.74% $0.68 a year
- Beta
- —
GRX key metrics, 2008–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGRX valuation Price multiples at each fiscal year-end price.
GRX returns How much profit the business earns on the capital it uses.
GRX per-share figures Results divided by the shares outstanding at year-end.
GRX financial health Debt, liquidity and how easily interest is covered.
GRX efficiency & capital use Working capital cycle and where the cash goes.
GRX valuation history
GRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GRX cash returned to shareholders
GRX price vs earnings per share
GRX key metrics
2008–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $147.3M | $149.6M | $148.9M | $175.1M | $233.9M | $209.5M | $211.7M | $172.8M | $179.2M | — |
| Enterprise value | $218.0M | $149.7M | $202.2M | $215.1M | $313.9M | $249.5M | $211.8M | $172.8M | $179.2M | — |
| P/E ratio | 64.2 | — | 352.1 | — | 5.5 | 8.7 | 4.0 | — | 5.7 | — |
| Price / sales | 9.6 | 45.9 | 37.1 | — | 5.4 | 8.4 | 3.9 | — | 5.5 | — |
| Price / book | 0.9 | 0.9 | 0.8 | 0.9 | 0.9 | 0.9 | 0.7 | 0.6 | 0.6 | — |
| Price / free cash flow | 15.6 | 11.4 | — | 3.0 | — | 4.6 | — | — | — | — |
| Price / operating cash flow | 15.6 | — | — | 3.0 | — | 4.6 | — | — | — | — |
| EV / sales | 14.3 | 45.9 | 50.4 | — | 7.2 | 10.0 | 3.9 | — | 5.5 | — |
| EV / EBITDA | 45.7 | 55.8 | 63.1 | — | 7.3 | 10.3 | 4.0 | — | 5.7 | — |
| EV / free cash flow | 23.1 | 11.4 | — | 3.7 | — | 5.5 | — | — | — | — |
| Earnings yield | 1.6% | −0.2% | 0.3% | −27.1% | 18.3% | 11.5% | 25.1% | −1.3% | 17.7% | — |
| Free cash flow yield | 6.4% | 8.8% | −0.2% | 33.2% | −8.1% | 21.6% | — | — | — | — |
| Dividend yield | 6.9% | 6.3% | 6.7% | 9.4% | 7.1% | 5.0% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 9.9% | 9.2% | 13.4% | 33.2% | 9.0% | 40.6% | — | — | — | — |
| Share price at fiscal year-end | $9.63 | $9.64 | $9.33 | $10.28 | $13.57 | $11.95 | $11.52 | $9.25 | $10.32 | $4.68 |
| Per share | ||||||||||
| Revenue per share | $1.00 | $0.21 | $0.25 | $0.00 | $2.52 | $1.43 | $2.93 | $0.00 | $1.87 | — |
| Earnings per share | $0.15 | −$0.02 | $0.03 | −$2.78 | $2.48 | $1.38 | $2.89 | −$0.12 | $1.82 | — |
| Operating cash flow per share | $0.62 | −$0.15 | −$0.02 | $3.41 | −$1.10 | $2.58 | — | — | — | — |
| Free cash flow per share | $0.62 | $0.84 | −$0.02 | $3.41 | −$1.10 | $2.58 | — | — | — | — |
| Cash per share | $0.00 | — | $0.00 | $0.00 | — | $0.00 | — | $0.00 | — | — |
| Book value per share | $10.36 | $11.01 | $11.58 | $12.01 | $15.32 | $13.81 | $16.64 | $14.54 | $17.26 | — |
| Tangible book value per share | $10.36 | $11.01 | $11.58 | $12.01 | $15.32 | $13.81 | $16.64 | $14.54 | $17.26 | — |
| Dividends per share | $0.66 | $0.60 | $0.62 | $0.97 | $0.96 | $0.59 | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Debt per share | $4.62 | $0.00 | $3.34 | $2.35 | $4.65 | $2.28 | $0.00 | $0.00 | $0.00 | — |
| Shares outstanding | 15.3M | 15.5M | 16.0M | 17.0M | 17.2M | 17.5M | 18.4M | 18.7M | 17.4M | — |
| Change in shares outstanding | −1.5% | −2.7% | −6.3% | −1.1% | −1.7% | −4.6% | −1.6% | +7.6% | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 1.4% | −0.2% | 0.2% | −20.2% | 16.9% | 8.8% | 18.4% | −0.8% | 18.0% | −24.9% |
| Return on invested capital (ROIC) | 1.9% | 1.0% | 1.3% | −11.9% | 13.7% | 8.2% | 18.4% | −0.6% | 18.0% | −0.8% |
| Return on assets (ROA) | 1.0% | −0.1% | 0.2% | −15.8% | 13.4% | 8.1% | 18.3% | −0.8% | 17.9% | −24.4% |
| Return on tangible assets | 0.9% | −0.1% | 0.2% | −19.1% | 12.2% | 8.4% | 17.3% | −0.8% | 10.5% | −28.1% |
| Free cash flow margin | 61.8% | 402.2% | −8.9% | — | −43.6% | 180.9% | — | — | — | — |
| Income quality (OCF / net income) | 4.11 | — | −0.84 | — | −0.44 | 1.87 | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $70.7M | $10,103 | $53.3M | $40.0M | $80.1M | $40.0M | $88,980 | $120 | $28,040 | — |
| Cash & short-term investments | $17,977 | — | $2,368 | $50,486 | — | $11,786 | — | $6,265 | — | $722 |
| Net debt | $70.7M | $10,103 | $53.3M | $39.9M | $80.1M | $40.0M | $88,980 | −$6,145 | $28,040 | −$722 |
| Debt / equity | 0.45 | 0.00 | 0.29 | 0.20 | 0.30 | 0.17 | 0.00 | 0.00 | 0.00 | — |
| Debt / assets | 0.29 | 0.00 | 0.22 | 0.16 | 0.23 | 0.14 | 0.00 | 0.00 | 0.00 | — |
| Net debt / EBITDA | 14.83 | 0.00 | 16.64 | — | 1.87 | 1.65 | 0.00 | — | 0.00 | — |
| Current ratio | 0.03 | 2.35 | — | 1.89 | 0.08 | 1.40 | 0.66 | 1.90 | 8.17 | — |
| Quick ratio | 0.03 | 2.35 | — | 1.89 | 0.08 | 1.40 | 0.66 | 1.90 | 8.17 | — |
| Interest coverage | 1.9 | 0.9 | 1.2 | -13.9 | 22.1 | 418.5 | — | — | — | — |
| Working capital | −$12.1M | $247,734 | $780,704 | $3.1M | −$5.8M | $1.5M | −$191,907 | $191,226 | $4.2M | — |
| Invested capital | $229.2M | $170.9M | $238.1M | $244.6M | $344.0M | $282.2M | $305.9M | $271.6M | $299.7M | $52.6M |
| Tangible asset value | $158.5M | $170.9M | $184.8M | $204.7M | $264.0M | $242.2M | $306.5M | $271.6M | $299.7M | $52.6M |
| Net current asset value | −$83.0M | −$54.4M | −$53.5M | −$37.4M | −$86.4M | −$39.2M | −$191,907 | −$285,028 | $3.8M | — |
| Graham number | $5.91 | — | $2.63 | — | $29.23 | $20.70 | $32.91 | — | $26.62 | — |
| Graham net-net per share | −$5.43 | −$3.51 | −$3.36 | −$2.29 | −$5.02 | −$2.31 | −$0.02 | −$0.02 | $0.15 | — |
| Capital allocation | ||||||||||
| Dividends paid | $10.1M | $9.4M | $9.9M | $16.5M | $16.5M | $10.4M | — | — | — | $423,722 |
| Share buybacks (net) | $4.4M | $4.5M | $9.9M | $41.6M | $4.4M | $74.6M | — | — | — | — |
| Dividend payout ratio | 442.3% | — | — | — | 38.7% | 43.1% | — | — | — | — |
| Dividends + buybacks / free cash flow | 153.9% | 105.5% | — | 99.9% | — | 188.0% | — | — | — | — |
| Capex / revenue | 0.0% | 0.0% | 0.0% | — | 0.0% | 0.0% | 0.0% | — | 0.0% | 0.0% |
| Capex / operating cash flow | 0.0% | — | — | 0.0% | — | 0.0% | — | — | — | — |
| Capex / depreciation | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| SG&A / revenue | 3.1% | 12.9% | 13.5% | — | 1.7% | 3.3% | 1.1% | — | 2.5% | 70.0% |
| Efficiency | ||||||||||
| Days sales outstanding | 9.8 | 67.0 | 336.4 | — | 23.4 | 40.1 | 2.6 | — | 34.4 | 267.5 |
| Days payables outstanding | 897.7 | 13.4 | 234.1 | 521.9 | 360.2 | 286.2 | 49.2 | 48.9 | 87.6 | 547.9 |
| Cash conversion cycle (days) | -887.9 | 53.5 | 102.2 | — | -336.8 | -246.2 | -46.6 | — | -53.2 | -280.4 |
| Receivables turnover | 37.39 | 5.45 | 1.09 | 0.00 | 15.57 | 9.11 | 138.56 | 0.00 | 10.61 | 1.36 |
| Payables turnover | 0.41 | 27.15 | 1.56 | 0.70 | 1.01 | 1.28 | 7.42 | 7.46 | 4.17 | 0.67 |
| Asset turnover | 0.07 | 0.01 | 0.02 | 0.00 | 0.14 | 0.08 | 0.19 | 0.00 | 0.18 | 0.01 |
| Average receivables | $408,528 | $597,968 | $3.7M | $3.6M | $2.8M | $2.7M | $387,957 | $2.6M | $3.1M | $658,302 |
| Average payables | $6.1M | $107,435 | $1.8M | $4.9M | $4.9M | $2.1M | $391,430 | $402,312 | $711,264 | $1.3M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from GRX's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GRX valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Gabelli Healthcare & Wellness traded at 64.2 times earnings, against a 10-year median of 7.2. Based on the latest twelve months, the trailing P/E is 17.7. Gabelli Healthcare & Wellness earned a return on equity of 1.4% and a return on invested capital of 1.9% in fiscal 2025. It ended the year with $70.7 million of debt and $0.0 million in cash and short-term investments, net debt of $70.7 million. It returned $14.5 million to shareholders: $10.1 million in dividends and $4.4 million in share buybacks, 154% of free cash flow.
See the GRX income statement, the GRX chart for price history, or the GRX stock overview for the latest quote and news.
GRX key metrics FAQ
What is Gabelli Healthcare & Wellness's P/E ratio?
Gabelli Healthcare & Wellness's trailing P/E ratio is 17.7 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was 64.2, compared with a 10-year median of 7.2.
What is Gabelli Healthcare & Wellness's EV/EBITDA?
Gabelli Healthcare & Wellness's enterprise value was 45.7 times EBITDA at the end of fiscal 2025 (enterprise value $218.0 million, EBITDA $4.8 million).
What is Gabelli Healthcare & Wellness's return on equity?
Gabelli Healthcare & Wellness's return on equity (ROE) was 1.4% in fiscal 2025: net income of $2.3 million on average shareholders' equity of $164.7 million.
What is Gabelli Healthcare & Wellness's ROIC?
Gabelli Healthcare & Wellness's return on invested capital was 1.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Gabelli Healthcare & Wellness have?
Gabelli Healthcare & Wellness had total debt of $70.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.45 and $70.7 million of net debt (14.83 times EBITDA).
What is Gabelli Healthcare & Wellness's dividend yield?
Gabelli Healthcare & Wellness's forward dividend yield is 6.74%. Gabelli Healthcare & Wellness paid $10.1 million in dividends in fiscal 2025 ($0.66 per share), a payout ratio of 442.3%.
Does Gabelli Healthcare & Wellness buy back its shares?
Yes. Gabelli Healthcare & Wellness spent $4.4 million on net share repurchases in fiscal 2025 Shares outstanding changed −1.5% over the year, to 15.3M..
What is Gabelli Healthcare & Wellness's free cash flow yield?
Gabelli Healthcare & Wellness generated $9.4 million of free cash flow in fiscal 2025, a free cash flow yield of 6.4% on its market value at year-end ($147.3 million).
What is Gabelli Healthcare & Wellness's current ratio?
Gabelli Healthcare & Wellness's current ratio was 0.03 at the end of fiscal 2025: current assets were 0.03 times current liabilities.